GLP-1 Cost Calculator🇺🇸

List price, cash pay, and insurance are not the same number

The headline number many people see first is the monthly list price, but that is not always what patients actually pay. A GLP-1 page that only quotes the list price misses the real-world search intent behind terms like Wegovy cost without insurance or Zepbound price with savings card. In practice, people care about the cash-pay route, the insurance route, and any manufacturer programme that sits between them.

That distinction also explains why Ozempic and Mounjaro often show up in the same search session as Wegovy and Zepbound. Ozempic and Mounjaro are diabetes brands, so some people encounter them through formulary coverage and copays, while the dedicated weight-management brands often face a steeper coverage hurdle.

This calculator therefore shows three separate lenses: an approximate current US list-price reference, an official cash or manufacturer-programme route where one is publicly published, and a low-end commercial-coverage scenario based on the current manufacturer copay offers. The annual figure is simply the monthly figure multiplied by 12, but the practical planning value comes from knowing which monthly number belongs to which access route.

How much do Wegovy, Zepbound, Ozempic, and Mounjaro cost on the current published routes?

For many users, the most useful comparison is not just brand against brand but list price against the current official route actually published by the manufacturer. The current manufacturer pages distinguish Wegovy's introductory starter pricing from its standard self-pay pen price, Zepbound's lower starter and 5 mg tiers from the higher-dose Self Pay Journey pricing, and Ozempic's starter pricing from its standard 1 mg and 2 mg cash tiers. Mounjaro's current manufacturer pricing, by contrast, points covered commercial users toward savings-card support but does not publish a broad uninsured self-pay price comparable to the Zepbound route, which is why this page separates the route labels instead of pretending the access rules are interchangeable.

At the same time, savings routes are not interchangeable. Eligibility, dose, refill timing, pharmacy channel, and insurance status can all change the number, and the quoted self-pay price is not the same thing as an insurance copay. Some searchers will also encounter other semaglutide offers or telehealth bundles, but this calculator stays with the included brand-name products so the brand-versus-brand comparison remains clear.

Why coverage and prior authorisation change the picture

Commercial insurance coverage for diabetes GLP-1 medications is usually easier to find than coverage for obesity treatment, although even diabetes coverage may require prior authorisation, step therapy, or specific diagnoses. Weight-management coverage depends heavily on employer plan design, and Medicare still handles obesity-drug coverage differently from many commercial plans.

That is the background behind search terms like does insurance cover Wegovy or why is Ozempic cheaper than Wegovy. The answer is often not the molecule alone but the labelled indication, the benefit design, and whether the plan treats obesity pharmacotherapy as a covered service at all.

The practical consequence is that a brand can look inexpensive in one scenario and far more expensive in another. Ozempic may look cheaper because a diabetes-label pathway and formulary coverage are more common for some users, while Wegovy or Zepbound may only become realistic when an employer plan covers obesity treatment or when a current manufacturer programme lowers the self-pay route.

How to read the cost chart and the brand comparison table

The chart on this page shows the selected monthly route for each brand at the same dose stage, which makes the gap between a cash route, a covered route, and a list-price reference easier to see at a glance. That matters because a table of numbers alone does not always make the budget shape obvious, especially when one or two brands are much cheaper only because a specific savings programme applies.

The comparison table underneath the chart keeps the selected dose, annualised total, list-price reference, and coverage context visible in one place. That lets you compare Wegovy against Zepbound, or Ozempic against Mounjaro, without forgetting whether you are looking at the obesity-label path, the diabetes-label path, or a published self-pay route. It is intentionally a planning view rather than a checkout quote.

Worked example: how the planning numbers diverge over a year

A typical planning comparison might look like this: a user pricing a weight-management route may see Wegovy at $349 per month after the starter offer, Zepbound at $399 to $449 depending on dose, and a list-price reference well above $1,000 per month if neither official cash route nor coverage applies. Over twelve months, that difference can shift the planning total by several thousand dollars even before considering refill timing or denied prior authorisation.

A diabetes-label user could see a different pattern. If an eligible covered-plan route lowers Ozempic or Mounjaro to a very low copay, the effective monthly planning number may sit far below the self-pay route for an obesity-label brand. That is why the most useful question is often not Which brand is cheapest? but Which route is realistic for my diagnosis, dose stage, and plan rules?

Manufacturer savings programmes, compounded alternatives, and what this tool does not

Manufacturer savings cards and direct pharmacy routes can lower the out-of-pocket price substantially for some patients, but the details change often. The useful question is not just whether a savings programme exists; it is whether you qualify, which doses are included, how long the offer lasts, and whether the refill cadence changes the price.

Compounded semaglutide and tirzepatide complicate cost comparisons further. They may appear far cheaper in search results, but they are not the same as comparing branded list price with official manufacturer cash-pay programmes. Compounded products are not FDA-approved finished drugs, and the regulatory context changes when branded shortage status changes.

This page also does not price telehealth membership fees, shipping surcharges, supplies, pharmacy dispensing differences, coupon exclusions, deductible accumulation, or non-US access routes. Use it to shortlist the most realistic next question, not as a checkout-ready quote.

Use the result as a shortlist, not a prescribing decision

Cost matters, but it is only one part of a GLP-1 decision. Indication, contraindications, dose tolerance, refill reliability, and the reason the medication is being prescribed can all matter more than the cheapest published route on a comparison page.

If you are choosing between branded options, managing diabetes, or using GLP-1 therapy under obesity treatment, review these numbers with your prescriber, pharmacist, or insurer before switching medication based on price alone. That is especially important when a low price depends on commercial coverage, on-label use, or a time-limited starter programme.

What hidden costs still need checking

Even a good cost calculator can miss expenses that show up later. Telehealth membership, pharmacy dispensing fees, shipping, sharps, insulin supplies, deductible resets, and refill timing rules can all move the true annual cost higher than the brand line on the page. Those are the kinds of costs people usually discover only after the first fill.

Compounded alternatives can also look attractive in a search result, but they are not the same thing as comparing branded list-price references with official savings programmes. If price is the main reason you are considering a switch, make sure you are comparing like with like before you change therapy.